Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3800 - ATTRACTION-05 (ONO-4538-38/BMS CA209844): A randomized, multicenter, double-blind, placebo- controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Immunotherapy;  Oesophageal Cancer;  Gastric Cancer


Masanori Terashima


Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369


M. Terashima1, Y. Kim2, T. Yeh3, H.C. Chung4, J. Chen5, N. Boku6, Y. Kang7, L. Chen8, M. Sasako9

Author affiliations

  • 1 Division Of Gastric Surgery, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2 Department Of Cancer Control And Population Health, Graduate School of Cancer Science and policy, National Cancer Center, Goyang/KR
  • 3 Department Of General Surgery, Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan/TW
  • 4 Division Of Medical Oncology, Department Of Internal Medicine, Yonsei Cancer Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, 120-752 - Seoul/KR
  • 5 Division Of Hematology/oncology, Department Of Internal Medicine, Linkou Chang Gung Memorial Hospital and Chang Gung University, 333 - Taoyuan/TW
  • 6 Gastrointestinal Medical Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 7 Department Of Oncology, University of Ulsan College of Medicine, Asan Medical Center, 138-736 - Seoul/KR
  • 8 National Institute Of Cancer Research, National Health Research Institutes and National Cheng Kung University Hospital, 704 - Tainan/TW
  • 9 Department Of Multidisciplinary Surgical Oncology, Hyogo College of Medicine, 663-8501 - Nishinomiya/JP


Abstract 3800


Nivo, a fully human IgG4 programmed death 1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated survival benefits across various tumor types. In ATTRACTION-02 (ONO-4538-12), a double-blind, placebo-controlled Phase 3 study in patients (pts) with unresectable advanced or recurrent G/EGJ cancer refractory to or intolerant of standard therapy, Nivo alone (3 mg/kg Q2W) achieved significant survival benefits (overall survival [OS] and progression free survival) vs. placebo with a manageable safety profile (Yoon-Koo Kang, et al. 2017 ASCO GI Cancers Symposium). In pStage II/III G/EGJ cancer, postoperative adjuvant chemotherapy with tegafur-gimeracil-oteracil potassium (S-1) or oxaliplatin/capecitabine (CapeOX) is indicated standard of care in Asian countries. However, the efficacy of these treatments is still unsatisfactory in pts with pStage III G/EGJ cancer, and thus a new treatment strategy is required. This multinational trial will evaluate the efficacy and safety of Nivo in combination with standard adjuvant chemotherapy in pts with pStage III G/EGJ cancer (ClinicalTrials.gov Identifier: NCT03006705).

Trial design

In this study, approximately 700 pts between 20 to 80 years of age with pStage III G/EGJ cancer after D2 or more extended lymph node dissection will be randomized to receive adjuvant chemotherapy (S-1 or CapeOX by investigator’s choice) + either Nivo or placebo. Treatment with Nivo, placebo, and S-1 therapy will be continued for up to 1 year, and CapeOX therapy will be administered for up to 6 months. Pts will be followed up for 5 years at maximum until consent withdrawal or the start of post-study treatment due to disease relapse. Primary endpoint is relapse free survival (RFS) by central assessment. Secondary endpoints are RFS by site investigator assessments, 3- and 5-year RFS rates by central and site investigator assessments, OS and 3- and 5-year OS rates. Japan, Korea, Taiwan and China will participate into the trial. This study has already started patient enrollment.

Clinical trial identification


Legal entity responsible for the study

Ono Pharmaceutical Co., Ltd


Ono Pharmaceutical Co., Ltd, Bristol-Myers Squibb


M. Terashima: Taiho, Chugai, Lilly Japan, Yakult, Daiichi-Sankyo. H.C. Chung: Lilly, GSK, MSD, Merck-Serono, BMS/Ono, Taiho, Celltrion, Quintiles, BMS. N. Boku: Ono, Taiho, Chugai, Eli-Lily. Y-K. Kang: Ono, Bristol-Myers Squibb, Lilly/ImClone, Taiho Pharmaceutical, Roche/Genentech, Novartis, Bayer. L-T. Chen: Ono Pharmaceutical Co., Ltd, Eli Lilly, MSD, PharmaEngine, Merrimack, TTY, Syncore, Five Prime, Novartis, GSK, Merck Serono, Polaris, anti-alpha enolase (ENO-1) monoclonal antibody/HuniLife. M. Sasako: Taiho, Chugai, Lilly, Yakult, Olympus, Daiichisankyo. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.